Acute Cellular Graft RejectionPhase 2NCT05499637
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
A Phase 2 study testing [68Ga]Ga-PentixaFor PET/CT in people with Acute Cellular Graft Rejection and Cardiac Sarcoidosis, run by John O. Prior at 1 site in Switzerland.
Trial summary
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Cellular Graft Rejection, Cardiac Sarcoidosis, Myocarditis Due to Drug
- What is being tested?
- [68Ga]Ga-PentixaFor PET/CT
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteSwitzerland
- Study dates
- 17 Jan 2023to 14 Sep 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- signed written informed consent
- male or female
- age ≥ 18 years
- patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)
- SOC clinical follow-up at the cardiology department in CHUV.
Who cannot join
- The presence of any one of the following exclusion criteria will lead to exclusion of the participant:
- absence of a signed written informed consent
- patients aged < 18 years
- claustrophobia
- myocardial ischemia in non-invasive perfusion test or coronarography in group II and III
- clinically unstable cardiovascular conditions, including:
Show all 17Show fewer
- clinically unstable brady-tachyarrhythmia
- severe and symptomatic hypo- or hypertension with documented systolic blood pressure < 90 mmHg or ≥220 mmHg respectively
- cardiogenic shock.
- women who are pregnant or breast feeding
- intention to become pregnant during the course of the study in group II
- previous enrolment into the current study
- moderate to severe renal insufficiency (GFR < 45 mL/min/1,73 m2), with contra-indication to the administration of Gadolinium in group II and III
- enrollment of the investigator, his/her family members, employees and other dependent persons
- history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
- insufficient knowledge of project language, inability to give consent or to follow procedures
- the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, 1011
About this study
Official title: Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.
Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of [68Ga]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.
The identification of a correlation between [68Ga]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.
Read the detailed description
Imaging will consist of administration of maximum 50 µg IV PentixaFor, labelled with 150 ±15 MBq of 68Ga, as bolus injection 60 ±15 minutes prior PET/CT
- Being tested
- [68Ga]Ga-PentixaFor PET/CT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
[68Ga]Ga-PentixaFor PET/CTDrug
Also called no other intervention name
[68Ga]Ga-PentixaFor PET/CT
| Study group | Role | What they receive |
|---|---|---|
| acute cellular cardiac allograft rejection | Experimental | [68Ga]Ga-PentixaFor PET/CT Receives: Drug: [68Ga]Ga-PentixaFor PET/CT |
| cardiac sarcoidosis | Experimental | [68Ga]Ga-PentixaFor PET/CT Receives: Drug: [68Ga]Ga-PentixaFor PET/CT |
| immune checkpoint inhibitor induced myocarditis | Experimental | [68Ga]Ga-PentixaFor PET/CT Receives: Drug: [68Ga]Ga-PentixaFor PET/CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion number
lesion number imaged
Measured: 1 year
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion site
lesion sites imaged
Measured: 1 year
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - SUV
standard uptake value
Measured: 1 year
Secondary outcomes (1)
to assess toxicity data
analysis of collected AEs classified according to CTCAE version 5.0
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2022
- Study start17 Jan 2023
- Primary completion14 Sep 2026
- Study completion14 Sep 2026
Why it stopped: Recruitment difficulties
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Cellular Graft RejectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- John O. Prior
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, John O. Prior, University of Lausanne Hospitals
- Investigators
- John O Prior, MD, PhD, Study chair, University of Lausanne Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05499637
- Sponsor's protocol ID
- 2022-00425
- Status last verified
- Oct 2026
- First submitted
- 22 Jun 2022
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation
- ClinicalTrials.gov ID
- NCT05499637
- Acronym / sponsor ID
- 2022-00425
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Recruitment difficulties
- Enrolment
- 25 participants (actual)
- Lead sponsor
- John O. PriorUniversity, hospital or other
- Study start
- 17 Jan 2023 (actual)
- Primary completion
- 14 Sep 2026 (actual)
- Study completion
- 14 Sep 2026 (actual)
- First posted
- 12 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.
Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of [68Ga]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.
The identification of a correlation between [68Ga]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.
Detailed description
Imaging will consist of administration of maximum 50 µg IV PentixaFor, labelled with 150 ±15 MBq of 68Ga, as bolus injection 60 ±15 minutes prior PET/CT
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| acute cellular cardiac allograft rejection | Experimental | Drug: [68Ga]Ga-PentixaFor PET/CT[68Ga]Ga-PentixaFor PET/CT |
| cardiac sarcoidosis | Experimental | Drug: [68Ga]Ga-PentixaFor PET/CT[68Ga]Ga-PentixaFor PET/CT |
| immune checkpoint inhibitor induced myocarditis | Experimental | Drug: [68Ga]Ga-PentixaFor PET/CT[68Ga]Ga-PentixaFor PET/CT |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- signed written informed consent
- male or female
- age ≥ 18 years
- patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)
- SOC clinical follow-up at the cardiology department in CHUV.
Key exclusion criteria (17 listed)
- The presence of any one of the following exclusion criteria will lead to exclusion of the participant:
- absence of a signed written informed consent
- patients aged < 18 years
- claustrophobia
- myocardial ischemia in non-invasive perfusion test or coronarography in group II and III
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| [68Ga]Ga-PentixaFor PET/CTAlso: no other intervention name[68Ga]Ga-PentixaFor PET/CT | Drug | acute cellular cardiac allograft rejection, cardiac sarcoidosis, immune checkpoint inhibitor induced myocarditis |
Primary outcome
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion number
Time frame: 1 year
lesion number imaged
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion site
Time frame: 1 year
lesion sites imaged
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - SUV
Time frame: 1 year
standard uptake value
1 secondary outcome
to assess toxicity data
Time frame: 1 year
Results and safety
The study was stopped early (reason given: Recruitment difficulties). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Cellular Graft Rejection
RecruitingPhase 1
A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
RecruitingEarly Phase 1
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Hematologic Malignancy, Bone Marrow Transplant Rejection
Active, not recruitingObservational study
Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients
Rejection Acute Renal, Rejection Chronic Renal
RecruitingPhase 3
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
RecruitingObservational study
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Acute Rejection of Renal Transplant, Graft Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John O Prior, MD, PhD study chair
University of Lausanne Hospitals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing [68Ga]Ga-PentixaFor PET/CT in people with Acute Cellular Graft Rejection and Cardiac Sarcoidosis, run by John O. Prior at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Recruitment difficulties). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Imaging results obtained by [68Ga]Ga-PentixaFor PET/CT - lesion number (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.